Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
The "Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034" report has been added tAndMarkets.com's offering.The report delivers an in-depth understanding of the Cough in ...
Long-term exposure to toxic air pollutants, particularly carcinogens like benzene, formaldehyde, and polycyclic aromatic ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
It closed Monday at $3.07, down more than 60%. Idiopathic pulmonary fibrosis, or IPF, is a particularly devastating disease. With no known cause, it leads to scarring of lung tissue until those ...
Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Pliant Therapeutics halted new enrollment in its BEACON-IPF trial after a safety board review. A separate study showed ...
Pliant Therapeutics (PLRX) announced that, per the charter of the trial’s independent Data Safety Monitoring Board, DSMB, the Company has ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback